The U.S. Food and Drug Administration (FDA) has increasingly emphasized the use of real-world evidence (RWE) to support regulatory decision-making for medical devices. As medical technologies evolve and data sources expand, the FDA states that RWE offers an important complement to traditional clinical investigations by reflecting how devices perform in routine clinical practice. Recent FDA publications clarify how the agency defines RWE, where it can be used, and the expectations sponsors should meet when relying on these data. These efforts are rooted in the 21st Century Cures Act, which directed FDA to evaluate the potential use of RWE to support regulatory decision‑making.
Defining Real-World Data and Real-World Evidence
The FDA distinguishes between real-world data (RWD) and real-world evidence. Real-world data are data relating to patient health status or the delivery of health care that are routinely collected from a variety of sources. These sources may include electronic health records, medical claims and billing data, product and disease registries, and data collected from digital health technologies. Real-world evidence, by contrast, is the clinical evidence derived from the analysis of RWD regarding the usage, benefits, or risks of a medical device .
This distinction is relevant to the FDA’s framework. Not all real-world data are suitable for regulatory purposes, and real-world evidence depends on whether the underlying data are relevant and reliable for the regulatory question being addressed.
Regulatory Uses of Real-World Evidence
According to FDA guidance, RWE may be used to support a range of regulatory decisions across the total product life cycle of a medical device. These decisions include premarket submissions, such as premarket notification (510(k)) submissions, premarket approval (PMA) applications, and De Novo classification requests, as well as postmarket requirements and surveillance activities.
The FDA has also highlighted that RWE can be particularly useful for evaluating device performance in broader or more diverse patient populations than those typically enrolled in traditional clinical trials, when appropriately evaluated. In some cases, RWE may help address questions related to long-term safety, rare adverse events, or device use in real-world clinical settings that are difficult to study through randomized controlled trials alone.
The FDA evaluates RWE based on two core criteria: relevance and reliability. Relevance refers to whether the data are appropriate to address the specific regulatory question, including whether the population, device, and clinical outcomes align with the intended use. Reliability focuses on the quality of the data and the methods used to collect and analyze them, including data completeness, accuracy, and consistency. The FDA has noted that sponsors should demonstrate that their data sources are fit for purpose. This may involve describing data provenance, data collection processes, and methods for addressing missing or inconsistent data. The FDA emphasizes that transparent and scientifically sound study designs remain critical, even when using observational data sources.
The FDA has undertaken multiple initiatives to advance the use of RWE for medical devices. These include the development of national and international device registries, participation in coordinated registry networks, and efforts to modernize post market survey systems. Through these initiatives, the agency aims to improve data quality and facilitate the generation of meaningful evidence from routine clinical care. The FDA has also released guidance documents to provide clarity to industry on how RWE may be incorporated into regulatory submissions. These documents are intended to promote consistency, predictability, and early engagement between sponsors and the agency when RWE is being considered.
Practical Implications for Device Manufacturers
For medical device manufacturers, the FDA’s approach to RWE underscores the importance of early planning. Companies considering RWE may consider engaging with the FDA to discuss data sources, study design, and analytical methods before submitting a regulatory application. While the FDA is clear that RWE does not eliminate the need for traditional clinical evidence in all cases, it may offer a flexible pathway to support regulatory decisions. As the FDA continues to refine its policies, RWE is expected to play an increasingly significant role in demonstrating the safety and effectiveness of medical devices throughout their life cycle.
Subscribe for News and Updates
